Vertex Pharmaceuticals (VRTX)
Health Care5 articles
Price chart
Why is VRTX moving today?
-0.3%VRTX is -0.3% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 7 hours ago
Vertex Pharmaceuticals (VRTX) overview
Vertex Pharmaceuticals is a biotech known for its cystic-fibrosis therapies. It is a member of the S&P 500 and is classified in the Health Care sector - pharmaceutical, biotech, device and managed-care companies.
Vertex Pharmaceuticals trades on the NasdaqGS under the ticker symbol VRTX. As of the most recent market data, the stock was priced around $513.26, down 0.27% on the session, giving Vertex Pharmaceuticals a market capitalization of roughly $130.09B.
Over the past 52 weeks, VRTX has traded between $374.17 and $560.25. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 29.9, a common gauge of how richly the market prices the company's earnings.
Key statistics
Source: Yahoo Finance - quote as of 7 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch VRTX
As one of the larger companies in the Health Care sector, Vertex Pharmaceuticals is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch VRTX for earnings reports, analyst rating changes, and headlines that can shift sentiment - each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, Vertex Pharmaceuticals's size means its share-price moves can also nudge the index as a whole, making VRTX a stock that even index investors pay attention to.
Market Mood
Latest VRTX news
Vertex (VRTX) Named Top Biotech Stock After Rival Drug Fails
Bernstein has identified Vertex Pharmaceuticals (VRTX) as its top biotechnology stock pick following the failure of a competing drug. This development is significant for investors as it highlights Vertex's competitive positioning in the market. The analyst report suggests that this could boost Vertex's stock performance amid shifts in the biotech sector. Observers should monitor how this news affects trading volumes for Vertex shares moving forward.
Read More: Vertex (VRTX) Named Top Biotech Stock After Rival Drug Fails
XLV vs PBE: Comparing Two Healthcare ETFs for Investors
The State Street Health Care Select Sector SPDR ETF (XLV) has an expense ratio of 0.08% and offers a yield of 1.6%, while the Invesco Biotechnology & Genome ETF (PBE) has a 0.58% expense ratio and a yield of 1.7%. XLV includes 60 holdings like Eli Lilly & Co (NYSE:LLY) at 16.5% and Johnson & Johnson (NYSE:JNJ) at 10.6%. In contrast, PBE holds 30 companies, with Vertex Pharmaceuticals (NASDAQ:VRTX) at 5.2% and Biogen Inc (NASDAQ:BIIB) at 5.1%. This comparison helps investors weigh low-cost sector exposure versus targeted growth potential in biotechnology.
Read More: XLV vs PBE: Comparing Two Healthcare ETFs for Investors
Vertex (VRTX) Stock Rating Reiterated After Crinetics Deal
Canaccord has reiterated its rating for Vertex Pharmaceuticals (VRTX) following the company's deal with Crinetics Pharmaceuticals. This decision reflects confidence in Vertex's growth potential influenced by strategic partnerships. Market analysts point out that such collaborations can significantly enhance Vertex's product pipeline and leverage its position in the biopharmaceutical space. For investors, understanding analyst ratings and strategic moves like this can provide insights into potential stock performance.
Read More: Vertex (VRTX) Stock Rating Reiterated After Crinetics Deal
Vertex Pharmaceuticals (VRTX) Form 144 Filed on June 18
Vertex Pharmaceuticals Inc. (VRTX) filed Form 144 on June 18, which allows for the sale of restricted securities. The form indicates that there may be upcoming stock sales by the company's affiliates. Such filings are essential as they provide transparency regarding insider trading activities and can impact investor sentiment. Understanding the details of these transactions can help investors gauge market movements and the potential supply of shares.
Read More: Vertex Pharmaceuticals (VRTX) Form 144 Filed on June 18
Premarket Movers: Kohl's, Casey's, and Vertex Show Significant Activity
In early trading, Kohl's, Casey's General Stores, and Vertex Pharmaceuticals emerged as the stocks with the largest price movements. Such fluctuations are significant as they can indicate investor sentiment and potential shifts in market trends. Increased volatility in these stocks may attract attention from traders looking for short-term gains, impacting overall market liquidity. Monitoring these movements could provide insights into retail and pharmaceutical sectors.
Read More: Premarket Movers: Kohl's, Casey's, and Vertex Show Significant ActivityMore Health Care stocks
Frequently asked questions
Is Vertex Pharmaceuticals in the S&P 500?
Yes. Vertex Pharmaceuticals (VRTX) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is VRTX in?
Vertex Pharmaceuticals is classified in the Health Care sector of the S&P 500 - pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest VRTX news?
This page collects recent Vertex Pharmaceuticals (VRTX) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Vertex Pharmaceuticals's stock price?
As of the most recent market data, Vertex Pharmaceuticals (VRTX) traded at approximately $513.26. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Vertex Pharmaceuticals's market cap?
Vertex Pharmaceuticals has a market capitalization of roughly $130.09B, based on its most recent share price and shares outstanding.
What is VRTX's P/E ratio?
VRTX trades at a trailing price-to-earnings ratio of about 29.9. The P/E ratio compares a company's share price to its earnings per share.